Melanoma/Skin Cancer News

Patients participating in clinical trials for anticancer drugs do not gain a survival benefit compared with individuals who received routine care, according to study results published in JAMA.

The prospect of screening for multiple cancer types simultaneously through a blood draw or other simple methods has generated tremendous excitement.

Certain individuals with non-cell lung cancer who experienced immune-related adverse events due to immune checkpoint inhibitor therapy had improved survival outcomes, according to retrospective study data published in JAMA Network Open.

AI could have the ability to answer some patient questions on cancer instead of clinicians, reducing clinician burdens and improving access to care, according to study results published in JAMA Oncology.

Actinic keratosis lesions were reduced and quality of life improved following once-daily topical tirbanibulin treatment, according to a study.

The gap in cancer mortality between Black and white individuals shrunk dramatically during the past 3 decades, according to a new report.

Procedural factors influence post-inflammatory hyperpigmentation following Mohs micrographic surgery among patients with skin of color, according to a study.

Merck has discontinued the vibostolimab and pembrolizumab coformulation arm of its phase 3 trial for the adjuvant treatment of patients with resected high-risk melanoma, the company announced in a press release.

Immunotherapy is a life-saving treatment for melanoma, but not all individuals have access to this treatment, according to a study.

As April is Skin Cancer Awareness Month, Healio has compiled the top skin cancer news and stories from 2024.